Biopolym. Cell. 2014; 30(3):203-208.
Структура и функции биополимеров
Влияние некоторых биологически активных веществ на содержание белков MGMT и MARP в клетках человека in vitro
1Коцаренко Е. В., 1Лыло В. В., 1Мацевич Л. Л., 1Рубан Т. А., 2Лучакивская Ю. С., 2Кучук Н. В., 1Лукаш Л. Л.
  1. Институт молекулярной биологии и генетики НАН Украины
    ул. Академика Заболотного, 150, Киев, Украина, 03680
  2. Институт клеточной биологии и генетической инженерии НАН Украины
    ул. Академика Заболотного, 148, Киев, Украина, 03680

Abstract

Цель. Исследовать влияние биологически активных соединений IFN-α2b, EMAP II, среды Card и фибронектина на содержание белков MGMT (О6-метилгуанин-ДНК метилтрансфераза) и MARP (белок, распознаваемый анти-MGMT антителами) в клетках человека in vitro. Методы. Клетки человека линий 4BL, Hep-2 и A102 обрабатывали ростовыми факторами и цитокинами. Изменения в количестве белков MGMT и MARP исследовали с использованием Вестерн блот анализа и моноклональных анти-MGMT антител. Результаты. Обработка клеток А102 препаратами EMAPII, фибронектина, Лаферона и среды Card снижает количество белка MGMT на фоне значительного возрастания количества белка MARP в этих клетках. Обработка рекомбинантным белком IFN-α2b увеличивает количество белков MGMT и MARP в клетках Hep-2, а экстрактами трансгенных растений, содержащих человеческий IFN-α2b, – существенно снижает количество обоих белков в клетках Hep-2 и MARP в клетках 4BL. Выводы. MGMT и MARP являются высокоиндуцибельными белками. Их количество может варьировать под действием некоторых ростовых факторов (среда Card и фибронектин), цитокина (IFN-α2b) цитокиноподобного (EMAP II) и цитокинсодержащих (Лаферон и IFN-α2b в композиции с растительными экстрактами) препаратов. Выявленная регуляция зависит не только от типа биологически активных веществ, но и от клеточных линий, использованных в экспериментах.
Keywords: линии клеток человека, репаративный фермент MGMT, MARP, цитокины, ростовые факторы, Вестерн-блот анализ

References

[1] Pegg AE. Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. Chem Res Toxicol. 2011;24(5):618-39.
[2] Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296-307.
[3] Christmann M, Kaina B. Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Res. 2013;41(18):8403–20.
[4] Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, Yoshida J. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 2005;65(17):7573-9.
[5] Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst). 2007;6(8):1079-99.
[6] Natsume A, Wakabayashi T, Ishii D, Maruta H, Fujii M, Shimato S, Ito M, Yoshida J. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol. 2008;61(4):653-9.
[7] Rosati SF, Williams RF, Nunnally LC, McGee MC, Sims TL, Tracey L, Zhou J, Fan M, Ng CY, Nathwani AC, Stewart CF, Pfeffer LM, Davidoff AM. IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression. Mol Cancer Ther. 2008;7(12):3852-8.
[8] Zheng M, Bocangel D, Ramesh R, Ekmekcioglu S, Poindexter N, Grimm EA, Chada S. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther. 2008;7(12):3842-51.
[9] Cardozo AK, Kruh?ffer M, Leeman R, Orntoft T, Eizirik DL. Identification of novel cytokine-induced genes in pancreatic beta-cells by high-density oligonucleotide arrays. Diabetes. 2001;50(5):909-20.
[10] Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, Abe T, Namba H, Wakai K, Wakabayashi T. Benefits of interferon-? and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer. 2011;117(8):1721-30.
[11] Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess. 2000;4(33):1-67.
[12] Reznikov AG, Chaykovskaya LV, Polyakova LI, Kornelyuk AI, Grygorenko VN. Cooperative antitumor effect of endothelial-monocyte activating polypeptide II and flutamide on human prostate cancer xenografts. Exp Oncol. 2011;33(4):231-4.
[13] Briegert M, Enk AH, Kaina B. Change in expression of MGMT during maturation of human monocytes into dendritic cells. DNA Repair (Amst). 2007;6(9):1255-63.
[14] Lukash LL, Iatsyshyna AP, Kushniruk VO, Pidpala OV. Reprogramming of somatic cells of adults in vitro. Topics in experimental evolution of organisms. 2011; 11: 493–8.
[15] Luchakivskaya Y, Kishchenko O, Gerasymenko I, Olevinskaya Z, Simonenko Y, Spivak M, Kuchuk M. High-level expression of human interferon alpha-2b in transgenic carrot (Daucus carota L.) plants. Plant Cell Rep. 2011;30(3):407-15.
[16] Lukash LL. Cell therapy of heart pathologies. Biotekhnolohiia. 2008;1(1):40–5.
[17] Lylo VV, Matsevich LL, Kotsarenko EV, Babenko LA, Korneliuk AI, Sukhorada EM, Lukash LL. Induction of repair enzyme O6-methylguanine-DNA methyltransferase gene expression under the influence of cytokine EMAP II in human cells in vitro. Tsitol Genet. 2011;45(6):53-60.
[18] Morten JE, Margison GP. Increased O6-alkylguanine alkyltransferase activity in Chinese hamster V79 cells following selection with chloroethylating agents. Carcinogenesis. 1988;9(1):45-9.
[19] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680-5.
[20] Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
[21] Aldridge GM, Podrebarac DM, Greenough WT, Weiler IJ. The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting. J Neurosci Methods. 2008;172(2):250-4.
[22] Eaton SL, Roche SL, Llavero Hurtado M, Oldknow KJ, Farquharson C, Gillingwater TH, Wishart TM. Total protein analysis as a reliable loading control for quantitative fluorescent Western blotting. PLoS One. 2013;8(8):e72457.
[23] Kotsarenko KV, Lylo VV, Macewicz LL, Babenko LA, Kornelyuk AI, Ruban TA, Lukash LL. Change in the MGMT gene expression under the influence of exogenous cytokines in human cells in vitro. Cytol Genet. 2013; 47(4):202–9.
[24] Chen Z, Shen D, Wang J, Yang Q. Effect of interferon-a/b on temozolomide activity against MGMT-positive glioma stem-like cells in vitro and in vivo. J Clin Oncol. 2012;30 (suppl):e12503.
[25] Lavon I, Fuchs D, Zrihan D, Efroni G, Zelikovitch B, Fellig Y, Siegal T. Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase. Cancer Res. 2007;67(18):8952-9.
[26] Macewicz LL, Kushniruk VO, Iatsyshyna AP, Kotsarenko KV, Lylo VV, Akopyan GR, Huleuk NL, Mykytenko DO, Lukash LL. Correlation of mutagenesis level with expression of reparative enzyme O6-methylguanine DNA methyltransferase during establishment of cell lines in vitro. Biopolym Cell. 2013;29 (6): 480–6.
[27] Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, Chan TA, Riggins GJ. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 2013;4(10):1737–47.
[28] Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–9.
[29] Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guarrasi R, Lanna M, Cennamo G, Faiola V, Del Prete S. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010;28(4):543-8.